Back

Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO

27 August 2017 (11:55 - 12:00)
Organised by:
Congress Presentation Part of: Do we need PCSK9 inhibitors in post-MI patients? Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Marc Sabatine

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

7 More presentations in this session

Presentation thumbnail
Opening question.
Slides Video
Presentation thumbnail
Positioning of the topic - The PCSK9 story .. so far
Professor F. Mach (Geneva, CH)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? PRO
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? CON
Professor H. Drexel (Feldkirch, AT)
Slides Video
Presentation thumbnail
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON
Professor H. Drexel (Feldkirch, AT)
Video

Access the full session

Session thumbnail
Do we need PCSK9 inhibitors in post-MI patients?

The Event

Event poster

ESC Congress 2017

27 August 2017 11:55 CET
You may be interested in
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Effects of PCSK9 inhibitor on adverse limb outcomes in patients with critical limb ischemia
28 August 2020
thumbnail
Congress Presentation
Characteristics of patients initiating PCSK9i mAb following myocardial infarction and comparability of treatment groups in the Netherlands
28 August 2023
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources